AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Candel Therapeutics, Inc. Director's Dealing 2021

Jul 27, 2021

33336_dirs_2021-07-26_7f48b16e-3b46-4936-a392-e8833259e826.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Caffo Nathan (Chief Business Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.55	2030-10-09	Common Stock (296144)		Direct

Footnotes

F1: 25% of this option shall vest and become exercisable on September 24, 2021, with the remainder vesting in 36 substantially equal monthly installment thereafter.